Hormonal
Infusion of PYY3-36 at supraphysiological doses (0.8 pmol/kg/min) significantly reduces energy intake in both lean and obese subjects, primarily through increased sympathoadrenal activity (thermogenesis and lipolysis), though this effect is accompanied by significant side effects like nausea.
Infusing PYY3-36 at high doses significantly cuts food intake, but it comes with a high cost of nausea and discomfort. The current delivery method (infusion) creates a narrow therapeutic window where effective doses cause significant side effects. Until administration methods can provide stable plasma levels without these peaks, this hormone is not a practical standalone solution for obesity management via this route.
PYY3–36 at 0.8 pmol (cid:1) kg(cid:1)1 (cid:1) min(cid:1)1 produced reduced EI... PYY3–36 caused increased thermogenesis, lipolysis, postprandial insulin and glucose responses, suggestive of increased sympathoadrenal activity.
Why this rating
Randomized, blinded, crossover study with healthy male subjects, though the high-dose PYY3-36 arm had low completion rates (n=4) due to side effects.
Source
Effects of PYY<sub>1–36</sub>and PYY<sub>3–36</sub>on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects
Birgitte Sloth et al. · American Journal of Physiology-Endocrinology and Metabolism · 2006
DOI 10.1152/ajpendo.00450.2006
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →